China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

China Approves HERNEXEOS for HER2-Mutant Advanced NSCLC

Boehringer Ingelheim's HERNEXEOS (zongertinib tablets) has received conditional approval from China's National Medical Products Administration (NMPA) as an initial monotherapy for adult patients with unresectable, locally advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC). This approval, which follows U.S. accelerated approval, is based on data from the Phase Ib Beamion LUNG-1 trial. In a cohort of 74 treatment-naïve patients, HERNEXEOS demonstrated a robust objective response rate (ORR) of 75.7%, including 10.8% complete response and 64.9% partial response, with a median duration of response (mDoR) of 15.2 months.

• The conditional approval by China's NMPA for HERNEXEOS (zongertinib) as a first-line treatment for HER2-mutant advanced NSCLC addresses a significant unmet medical need in China, where lung cancer is a leading cause of cancer death. This regulatory milestone builds upon a prior Breakthrough Therapy Designation from China's CDE and U.S. accelerated approval, underscoring the recognized urgency and potential impact of this therapy.
• The approval is supported by compelling clinical efficacy data from the Phase Ib Beamion LUNG-1 trial, specifically from a cohort of 74 treatment-naïve patients. The trial demonstrated an impressive objective response rate (ORR) of 75.7%, with 10.8% of patients achieving a complete response and 64.9% achieving a partial response. Furthermore, the median duration of response (mDoR) was 15.2 months, indicating sustained clinical benefit.
• HERNEXEOS is an irreversible tyrosine kinase inhibitor (TKI) that selectively targets HER2 while sparing wild-type EGFR, a mechanism designed to minimize associated toxicities. The therapy exhibited a manageable safety profile, with predominantly low-grade treatment-related adverse events. In a pooled safety population of 177 patients, adverse events led to dose reductions in 9% and dose discontinuations in 6% of patients.

Addressing Critical Unmet Needs in HER2-Mutant NSCLC

Recent advances in HER2-mutant NSCLC have revealed significant heterogeneity within this patient population, highlighting the need for more nuanced treatment approaches. While trastuzumab deruxtecan has emerged as the first approved targeted therapy, several critical gaps remain in addressing the diverse clinical scenarios and molecular subtypes within this 2-4% subset of NSCLC patients.

• Non-exon 19/20 mutations: Evidence for trastuzumab deruxtecan (T-DXd) in patients with HER2 non-exon 19/20 mutations is scarce, representing an underserved population requiring validation in large-sample studies

• Primary resistance to T-DXd: Some cases are not responsive to T-DXd and the primary resistant mechanism remains unclear, requiring further investigation

• Central nervous system metastases: Mixed response in brain metastases observed with T-DXd, highlighting the need for further research in overcoming challenges related to CNS metastases

• Extracellular domain (ECD) mutations: NSCLCs harboring ECD-ERBB2 mutations (18-24% of ERBB2-mutant cases) are associated with a unique clinico-genomic phenotype and improved outcomes with first-line chemoimmunotherapy, with implications for optimizing treatment strategies

• Transmembrane/juxtamembrane domain (TMD/JMD) mutations: Represent 5-7% of ERBB2-mutant NSCLC cases with high rates of PIK3CA (24%) and RBM10 (18%) co-mutations, requiring specific treatment approaches

• Treatment sequencing optimization: HER3-positive patients who received chemotherapy before TKI demonstrated outcomes comparable to HER3-negative patients, raising the hypothesis that treatment sequencing may influence outcomes, though this requires prospective validation

• Alternative treatment options: Necessary to explore alternatives for HER2-mutant NSCLC patients in regions where trastuzumab emtansine is not approved

• Resistance mechanisms: HER2 heterogeneity and resistance mechanisms limit existing treatment options, requiring further improvements in HER2-directed therapy

• First-line treatment potential: While T-DXd is approved as subsequent-line therapy after failure with standard treatment, real-world cases support its therapeutic potential as first-line treatment in certain scenarios, requiring further investigation

• Molecular profiling importance: Need for molecular profiling to guide personalized treatment strategies, particularly given disease heterogeneity from ERBB2 activating mutations and co-occurring genomic alterations

Compelling Efficacy and Safety from Beamion LUNG-1

Recent clinical investigations have provided important insights into therapeutic approaches for HER2-mutant advanced non-small cell lung cancer through several key studies. The PUMA-NER-4201 (NCT01827267) and SUMMIT (NCT01953926) phase 2 studies evaluated neratinib-based therapies in ERBB2-mutant lung adenocarcinomas, enrolling 60 and 78 patients respectively. These studies investigated neratinib monotherapy, neratinib plus weekly temsirolimus, and neratinib plus trastuzumab administered every three weeks. The objective response rates demonstrated limited efficacy: neratinib monotherapy achieved 0% (95% CI, 0.0-19.5) in the 4201 study and 3.8% (95% CI, 0.1-19.6) in SUMMIT, while combination approaches showed modest improvements with neratinib plus temsirolimus achieving 14.0% (95% CI, 5.3-27.9) and neratinib plus trastuzumab reaching 9.6% (95% CI, 3.2-21.0).

Safety profiles varied across treatment regimens, with grade ≥3 treatment-related adverse events occurring in 23.5% to 34.6% of patients receiving neratinib monotherapy, 37.2% with neratinib plus temsirolimus, and 48.1% with neratinib plus trastuzumab. Despite generally limited overall activity, five patients with specific ERBB2 alterations including exon 20 insertions, L755P and D769Y missense mutations, and a novel ERBB2-SHC1 fusion achieved durable responses lasting ≥1 year across different treatment arms.

A real-world retrospective study conducted in China between 2023-2025 evaluated trastuzumab deruxtecan (T-DXd) in 35 patients with HER2-mutant advanced NSCLC receiving second- or further-line treatment. This study demonstrated more encouraging results with a median progression-free survival of 7.85 months (95% CI: 6.64-15.05) and an objective response rate of 51.4% (95% CI: 34.0-68.6%). The safety profile was notably favorable, with adverse events reported in 65.7% of patients, fatigue being the most common (40.0%), and no grade ≥3 adverse events observed during the median follow-up of 9.7 months.

HERNEXEOS's Impact on the Evolving Treatment Landscape

The treatment landscape for HER2-mutant advanced NSCLC has undergone significant transformation over the past five years, marked by regulatory milestones and expanding therapeutic options. Most notably, 2025 witnessed the FDA approval of zongertinib, the first HER2-specific TKI for previously treated ERBB2-mutated advanced NSCLC. Trastuzumab deruxtecan (T-DXd) received FDA and EMA approval for HER2-mutant NSCLC, demonstrating the most encouraging efficacy data among all anti-HER2 agents with a 55% response rate, median progression-free survival of 8.2 months, and median overall survival of 17.8 months. The 2023 NCCN guidelines now recommend antibody-drug conjugate trastuzumab emtansine for HER2-mutant lung cancer treatment, reflecting the growing evidence base for targeted approaches.

Novel therapeutic strategies have emerged through comprehensive clinical development programs spanning 2020-2023. A pivotal phase 2 basket study of trastuzumab deruxtecan enrolled 102 patients with HER2-mutant solid tumors, achieving an objective response rate of 29.4% with a median follow-up of 8.61 months, though adjudicated drug-related interstitial lung disease occurred in 11% of patients. HER2-specific TKIs have shown varying efficacy profiles, with pyrotinib demonstrating moderate efficacy in pooled analyses of 75 patients (28% ORR, 7.0 months median PFS), while patients with TP53 wild-type tumors achieved significantly superior outcomes including 97.1% disease control rate versus 68.8% in TP53-mutated cases. Combination strategies targeting both EGFR and HER2 pathways have shown promise in patients with concomitant mutations, while immunotherapy data revealed HER2 mutations derive greater benefit from immune checkpoint inhibitors compared to EGFR-sensitizing mutations, with disease control rates of 57% versus 18%.

The evolving understanding of resistance mechanisms and patient stratification has refined treatment approaches significantly. Analysis of pyrotinib resistance in 40 patients identified 12 secondary HER2 mutations in 38.7% of cases, with drug screening indicating mobocertinib and dacomitinib effectiveness against specific resistance variants. Patient population studies revealed that the 12 base pair in-frame insertion in exon 20 with p.771insAYVM represents the most common subtype, though patients with AYVM mutations showed poor clinical outcomes with median overall survival of 9.9 months. Future therapeutic development focuses on refining patient selection based on HER2 variant patterns, optimizing antibody-drug conjugate design to minimize toxicity while maintaining efficacy, and addressing challenges including intracranial activity and optimal therapy sequencing in this molecularly defined patient population.

Zongertinib's Expanding Clinical Program Beyond NSCLC

Zongertinib's clinical development program extends beyond NSCLC to encompass multiple HER2-driven malignancies through two major Phase II trials. These studies target both HER2-positive (overexpressed/amplified) and HER2-mutant solid tumors across diverse cancer types, employing both monotherapy and combination therapy approaches.

First-Line Breakthrough: Zongertinib's Impact on HER2-Mutant NSCLC

The recent conditional approval of HERNEXEOS (zongertinib) by China's NMPA for initial monotherapy in HER2-mutant non-small cell lung cancer (NSCLC) marks a pivotal moment for patients battling this aggressive disease. Historically, HER2-mutant NSCLC has presented a significant unmet need, with limited targeted options beyond chemotherapy or immunotherapy in the first-line setting. While trastuzumab deruxtecan has offered hope for pretreated patients, zongertinib's entry as a first-line targeted therapy in a major market like China could redefine the treatment landscape.

This approval is underpinned by compelling data from the Beamion LUNG-1 trial, showcasing a robust objective response rate of 75.7% and a median duration of response of 15.2 months in treatment-naïve patients. Zongertinib's distinct mechanism as an irreversible, HER2-selective tyrosine kinase inhibitor that specifically spares EGFR signaling is a critical differentiator. This selectivity is designed to enhance potency against HER2-driven cancers while mitigating the dose-limiting toxicities often associated with less selective pan-HER inhibitors. The manageable safety profile observed in clinical trials, with mainly low-grade adverse events and no reported drug-related interstitial lung disease in previously treated cohorts, further supports its potential as a well-tolerated first-line option.

However, the conditional nature of this approval necessitates ongoing confirmatory studies, which will be crucial for securing full approval and potentially expanding its label. Furthermore, while zongertinib has demonstrated efficacy in HER2-mutant NSCLC, the diverse nature of HER2 alterations, including non-tyrosine kinase domain mutations, suggests that continued research into optimal patient selection and potential differential responses across these genomic subtypes will be important. As Boehringer Ingelheim continues to explore zongertinib's potential in other HER2-altered solid tumors and in combination regimens, its strategic positioning in the first-line HER2-mutant NSCLC market provides a strong foundation for future growth and addresses a critical gap in precision oncology.